Averion Executive Chairman - Philip T. Lavin, Ph.D. - Co-Organized Session and Will...

Averion Executive Chairman - Philip T. Lavin, Ph.D. - Co-Organized Session and Will Be Honored as a Fellow at the American Statistical Association's Annual 2008 Joint Statistical Meeting

SOUTHBOROUGH, Mass.--(Business Wire)--
Averion International Corp. (OTC BB: AVRO), a clinical research
organization (CRO) specializing in oncology, cardiovascular diseases,
and medical devices, today announced that its Executive Chairman,
Philip T. Lavin, PhD, has co-organized a session on "Statistics in
Ophthalmology Clinical Trials" at the American Statistical
Association's (ASA) 2008 Joint Statistical Meeting. The meeting will
take place from August 3-7, 2008 at the Denver Convention Center, in
Denver, Colorado.

In addition, Dr. Lavin will be presented as one of the ASA's 2008
Fellows of the Association. Dr. Lavin has been elected as one of this
year's 53 Fellows of the Association. He receives this honor in
recognition of his outstanding professional contributions to and
leadership in the field of statistical science. He will be honored at
a ceremony on Tuesday, August 5, 2008.

The designation of Fellow has been a superlative honor in ASA for
more than 90 years. According to the association by-laws, each year
the Committee on Fellows can elect no more than one-third of one
percent of the total ASA membership as Fellows. Individuals are
nominated for the honor by fellow members and must have an established
reputation and have made outstanding contributions in some aspect of
statistical work to be selected.

About Averion International Corp.

Averion International Corp. is a leading international CRO with
proven expertise in supporting global clinical trials for
pharmaceutical, biotechnology and medical device companies. The
Company has a therapeutic focus in oncology, cardiovascular diseases
and medical devices. Averion's core competencies are in FDA and
product registration support, site selection, project management,
medical and site monitoring, data management, biometrics,
pharmacovigilance, medical writing, and full clinical trial management
services throughout the clinical trials lifecycle. The Company has
supported FDA approvals for products in many therapeutic areas
including oncology, cardiovascular diseases and medical devices.

Averion is headquartered in Southborough, Mass., with European
operations based in Basel, Switzerland. Averion has additional U.S.
offices in California, Maryland and New York; and additional offices
outside the U.S. in France, the Netherlands, the United Kingdom,
Poland, Russia, Israel, Germany, Austria, and Ukraine. We have
additional operation centers in the Czech Republic, Slovakia and
Hungary, and research partnerships in India, Asia and South America.
For more information, visit www.averionintl.com.

Forward-Looking Statement

Statements contained in this press release that are not historical
information are forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "anticipate," "intend," "plan," "estimate," "project," or
words of similar meaning, or future or conditional verbs such as
"will," "would," "should," "could," or "may." Such forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from those projected or implied.
Those risks and uncertainties include, but are not limited to: our
ability to attract, retain or integrate key personnel, including
scientific and technical personnel; the termination, modification or
delay of contracts which would, among other things, adversely impact
our recognition of revenue included in backlog and our cash-on-hand;
risks associated with our pursuit of strategic acquisitions or
investment in new markets; our ability to acquire and integrate new
businesses; our dependence on certain industries and clients; our
ability to adequately protect sensitive patient information and
confidential information of clients; our ability to keep pace with
rapid technological changes; fluctuation in our operating results; our
ability to service our outstanding debt and comply with requirements,
including financial covenants, associated with that debt; our ability
to recruit suitable volunteers for the clinical trials of our clients;
our exposure to exchange rate fluctuations and international economic,
political and other risks; our ability to develop and market new
services in the U.S., Europe and internationally; the highly
competitive nature of our market; our exposure to changes in
outsourcing trends in the pharmaceutical and biotechnology industries;
the impact of government regulation on our business; whether we can
achieve and maintain effective internal controls; and other risks.
Certain of these risks and uncertainties, in addition to other risks,
are more fully described in the Company's annual report on Form 10-KSB
for the period ending December 31, 2007 and in the Company's other
periodic reports filed with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date of this
press release, and the Company assumes no obligation to update or
revise the forward-looking statements, whether as a result of new
information, future events, or otherwise.

Media Contact:
Averion International Corp.
Gillian Dellacioppa, 508-597-6000
gillian.dellacioppa@averionintl.com
or
Investor Contact:
Averion International Corp.
Lawrence R. Hoffman, 508-597-6000
larry.hoffman@averionintl.com

Copyright Business Wire 2008